Human cytomegalovirus RNA vaccines
View Patent ↗The disclosure describes HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
1. A human cytomegalovirus (hCMV) vaccine comprising:
(a) at least one messenger ribonucleic acid (mRNA) polynucleotide comprising an open reading frame encoding a hCMV gH polypeptide; (b) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV gL polypeptide; (c) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV UL128 polypeptide; (d) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV UL130 polypeptide; (e) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV UL131A polypeptide; and (f) at least one mRNA polynucleotide comprising an open reading frame encoding a hCMV gB polypeptide, wherein the mRNA polynucleotides of (a)-(f) are formulated in at least one lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid, in an effective amount to induce an immune response in a subject administered at least one dose of the vaccine, and wherein the mRNA polynucleotides of (a)-(f) are not self-replicating RNA.
2. The hCMV vaccine of claim 1 , wherein the at least one mRNA polynucleotide of (a)-(f) further encodes at least one 5′ terminal cap, 7mG(5′)ppp(5′)NlmpNp.
3. The hCMV vaccine of claim 1 , wherein at least 80% of the uracil in the open reading frame of (a)-(f) have a chemical modification selected from N1-methyl-pseudouridine or N1-ethyl-pseudouridine.
4. The hCMV vaccine of claim 3 , wherein the chemical modification is in the carbon-5 position of the uracil.
5. The hCMV vaccine of claim 1 , wherein the efficacy of the vaccine in vaccinated subjects is at least 60%, relative to unvaccinated subjects, following a single dose of the vaccine.
6. The hCMV vaccine of claim 5 , wherein the efficacy of the vaccine in vaccinated subjects is at least 70%, relative to unvaccinated subjects, following a single dose of the vaccine.
7. The hCMV vaccine of claim 6 , wherein the efficacy of the vaccine in vaccinated subjects is at least 80%, relative to unvaccinated subjects, following a single dose of the vaccine.
8. The hCMV vaccine of claim 7 , wherein the efficacy of the vaccine in vaccinated subjects is at least 90%, relative to unvaccinated subjects, following a single dose of the vaccine.
9. The hCMV vaccine of claim 1 , wherein the effective amount is sufficient to produce detectable levels of hCMV gH, gL, UL128, UL130, UL131A and/or gB polypeptide as measured in serum of a subject vaccinated with at least one dose of the vaccine at 1-72 hours post administration.
10. The hCMV vaccine of claim 1 , wherein the effective amount is sufficient to produce a 1,000-10,000 neutralization titer produced by neutralizing antibody against the hCMV gH, gL, UL128, UL130, UL131A and/or gB polypeptide as measured in serum of a subject vaccinated with at least one dose of the vaccine at 1-72 hours post administration.
11. The hCMV vaccine of claim 1 , wherein an anti-hCMV gH, gL, UL128, UL130, UL131A and/or gB polypeptide antibody titer produced in a subject vaccinated with at least one dose of the vaccine is increased by at least 1 log relative to a control, wherein the control is an anti-hCMV gH, gL, UL128, UL130, UL131A and/or gB polypeptide antibody titer produced in a subject who has not been administered a vaccine against hCMV.
12. The hCMV vaccine of claim 1 , wherein the anti-hCMV gH, gL, UL128, UL130, UL131A and/or gB polypeptide antibody titer produced in a subject vaccinated with at least one dose of the vaccine is increased at least 2 times relative to a control, wherein the control is an anti-hCMV gH, gL, UL128, UL130, UL131A and/or gB polypeptide antibody titer produced in a subject who has not been administered a vaccine against hCMV.
13. The hCMV vaccine of claim 1 , wherein the effective amount is a total dose of 25 μg-200 μg.
14. The hCMV vaccine of claim 13 , wherein the effective amount is a total dose of 25 μg-100 μg.
15. The hCMV vaccine of claim 1 , wherein the ionizable cationic lipid comprises the following compound:
16. The hCMV vaccine of claim 1 , wherein the hCMV gH polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 59, the hCMV gL polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 61, the hCMV UL128 polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 63, the hCMV UL130 polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 65, the hCMV UL131A polypeptide comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 67, and/or the hCMV gB protein comprises an amino acid sequence that has at least 90% identity to the amino acid sequence of SEQ ID NO: 69.
17. The hCMV vaccine of claim 16 , wherein the hCMV gH polypeptide comprises the amino acid sequence identified by SEQ ID NO: 59, the hCMV gL polypeptide comprises the amino acid sequence identified by SEQ ID NO: 61, the hCMV UL128 polypeptide comprises the amino acid sequence identified by SEQ ID NO: 63, the hCMV UL130 polypeptide comprises the amino acid sequence identified by SEQ ID NO: 65, the hCMV UL131A polypeptide comprises the amino acid sequence identified by SEQ ID NO: 67, and/or the hCMV gB protein comprises the amino acid sequence identified by SEQ ID NO: 69.
18. The hCMV vaccine of claim 1 , wherein the at least one mRNA polynucleotide of (a) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 108, the at least one mRNA polynucleotide of (b) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 109, the at least one mRNA polynucleotide of (c) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 110, the at least one mRNA polynucleotide of (d) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 93, the at least one mRNA polynucleotide of (e) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 112, and/or the at least one mRNA polynucleotide of (f) comprises a sequence that has at least 90% identity to the nucleotide sequence of SEQ ID NO: 113.
19. A human cytomegalovirus (hCMV) vaccine comprising:
(a) at least one RNA polynucleotide comprising an open reading frame (ORF) that comprises the nucleotide sequence identified by SEQ ID NO: 108, (b) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO: 109, (c) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO: 110, (d) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO: 93, (e) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO: 112, and (f) at least one RNA polynucleotide comprising an ORF that comprises the nucleotide sequence identified by SEQ ID NO: 113, wherein the RNA polynucleotides of (a)-(f) are formulated in at least one lipid nanoparticle that comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid, in an effective amount to induce an immune response in a subject administered at least one dose of the vaccine.
20. The hCMV vaccine of claim 19 , herein the RNA polynucleotides of (a)-(f) are mRNA polynucleotides.